Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: Findit who wrote (99850)	12/1/2003 7:19:49 PM
From: Findit	Read Replies (2) \| Respond to of 208838

BSDM news on financing. Not sure how this will affect price tomorrow. - Monday December 1, 6:33 pm ET SALT LAKE CITY, Dec. 1 /PRNewswire-FirstCall/ -- BSD Medical Corp. (OTC Bulletin Board: BSDM - News) today announced, in conjunction with the company's annual 10-KSB filing, the following under Recent Developments within the filing: On November 28, 2003, we completed the sale of an aggregate of 1,820,000 shares of our common stock to three institutional investors. The shares of common stock were sold for cash consideration of $1.10 per share, or a total of $2,002,000, pursuant to the terms of the Securities Purchase Agreement entered into by and among the investors and our company as of November 28, 2003. These shares were issued in a private placement transaction pursuant to Section 4(2) and Regulation D under the Securities Act of 1933, as amended. As provided in the Securities Purchase Agreement, we also agreed to cause a shelf registration statement covering the resale of these shares to be filed no later than 60 days after the closing of the private placement. We estimate that our net proceeds from the transaction, after paying a commission to our placement agent, T.R. Winston & Company, LLC, and legal other expenses related to the transaction, will be approximately $1,850,000. We also have agreed to issue to our placement agent a three-year warrant to purchase up to 91,000 shares at an exercise price per share of $1.80 as provided in the Securities Purchase Agreement. About BSD Medical Corporation BSD Medical Corporation develops, manufactures, markets and services hyperthermia microwave systems used to treat cancer, the second leading cause of death in the United States according to the National Cancer Society. Our treatment systems precisely deliver microwave energy to elevate the temperature of cancerous tumors, directly killing cancerous cells and significantly enhancing the effectiveness of certain other cancer therapies. BSD also owns approximately 30% of TherMatrx, which markets a medical device that we developed for the treatment of benign prostatic hyperplasia, or BPH. BPH results from enlargement of the prostate as men age, and is a major health condition so prevalent that its symptoms affect over half of men by age 60 and 90% of men by age 85. In October 2003 BSD announced that the company had received FDA approval for a new operating system, allowing the commercial market introduction of a new family of six systems. BSD Medical is in aggressive pursuit of this commercial launch, as well as preparing for the FDA submission of another of its systems designed to treat deep cancers. For further information about BSD Medical, visit www.bsdmc.com . Statements contained in this press release that are not historical facts are forward looking statements, as that item is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties (detailed in the Company's filings with the Securities and Exchange Commission) that could cause actual results to differ materially from estimated results. -------------------------------------------------------------------------------- Source: BSD Medical Corporation